Toward a broader understanding of aldosterone in congestive heart failure

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 4, Issue 3, 2003, Pages 155-163

  Weber, Karl T ^a   Sun, Yao ^a   Wodi, Linus A ^a   Munir, Ahmad ^a   Jahangir, Eiman ^a   Ahokas, Robert A ^a   Gerling, Ivan C ^a   Postlethwaite, Arnold E ^a   Warrington, Kenneth J ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Aldosterone; Magnesium; Oxi nitrosative stress; Peripheral blood mononuclear cells

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; EPLERENONE; LOSARTAN; MAGNESIUM ION; MINERALOCORTICOID; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA;

ALDOSTERONE RELEASE; AUTOCRINE EFFECT; CEREBROSPINAL FLUID; CHOROID PLEXUS; CONGESTIVE HEART FAILURE; DIURESIS; ENDOTHELIUM CELL; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPOTHALAMUS PERIVENTRICULAR NUCLEUS; MAGNESIUM EXCRETION; NONHUMAN; PATHOPHYSIOLOGY; POTASSIUM EXCRETION; REVIEW; SODIUM ABSORPTION; SODIUM EXCRETION; SODIUM TRANSPORT; STEROIDOGENESIS; SYMPATHETIC TONE;

EID: 0242692730     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2003.024     Document Type: Review

References (131)

1. Tait SAS,Tait JF.The correspondence of S.A. S. Simpson and J. F. Tait with T. Reichstein during their collaborative work on the isolation and elucidation of the structure of electrocortin (later aldosterone). Steroids 1998;63:440-53.
2. Tait JF,Tait SAS. A decade (and even more) of aldosterone and other adrenal steroids. In: Biglieri EG, Melby JC (eds.). Endocrine Hypertension. New York: Raven Press; 1990;p. 5-27.
3. Selye H.The general adaptation syndrome and the diseases of adaptation. J Clin Endocrinol 1946;6:117-230.
4. Davis JO. The physiology of congestive heart failure. In: Hamilton WF (ed.) Handbook of Physiology. Washington, DC: American Physiological Society, 1965; p. 2071-122.
5. Davis JO. Mechanisms of salt and water retention in congestive heart failure. Am J Med 1960;29:486-506.
6. Kagawa CM, Cella JA, Van Arman CG. Action of new steroids in blocking effects of aldosterone and deoxycorticosterone on salt. Science 1957;126:1015-16.
7. Liddle GW.Aldosterone antagonists. AMA Arch Intern Med 1958;102:998-1004.
8. Coppage WS, Jr., Liddle GW. Mode of action and clinical usefulness of aldosterone antagonists. Ann N Y Acad Sci 1960; 88:815-21.
9. Weber KT, John B. Hickam Lecture: Heart-hitting tales of salt and destruction. J Lab Clin Med 2000;136:7-13.
10. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.
11. Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Cardiac Failure 1996;2:47-54.
12. Jorde UP, Vittorio T, Katz SD, Colombo PC, Latif F, Lejemtel TH. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 2002;106:1055-7.
13. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
14. Lösel RM, Feuring M, Falkenstein E, Wehling M. Nongenomic effects of aldosterone: cellular aspects and clinical implications. Steroids 2002;67:493-8.
15. Swaminathan R. Disorders of magnesium metabolism. J Int Fed Clin Chem 1999;11(2):10-18.
16. Mader IJ, Iseri LT. Spontaneous hypopotassemia, hypomagnesemia, alkalosis and tetany due to hypersecretion of corticosterone-like mineralocorticoid. Am J Med 1955;19:976-88.
17. Milne MD, Muehrcke RC, Aird I. Primary aldosteronism. Q J Med 1957;26:317-35.
18. Cope CL, Garcia-Llaurado J. The occurrence of electrocortin in human urine. BMJ 1954;1(June 5):1290-4.
19. Foye LV, Feightmeir TV. Adrenal cortical carcinoma producing solely mineralocorticoid effect. Am J Med 1955;19:966-75.
20. Hellem AJ. Primary aldosteronism. (Report of a case). Acta Med Scand 1956;155:271-4.
21. Eales L, Linder GC. Primary aldosteronism. Some observations on a case in a Cape Coloured woman. Q J Med 1956;25: 539-55.
22. van Buchem FSP, Doorenbos H, Elings HS. Primary aldosteronism due to adrenocortical hyperplasia. Lancet 1956;2(Aug 18):335-7.
23. Campbell CH, Nicolaides N, Steinbeck AW. Adrenocortical tumour with hypokalæmia and flaccid muscle paralysis. Lancet 1956;2:553-5.
24. Chalmers TM, FitzGerald MG, James AH, Scarborough H. Conn's syndrome with severe hypertension. Lancet 1956;1: 127-32.
25. Horton R, Biglieri EG. Effect of aldosterone on the metabolism of magnesium. J Clin Endocrinol Metab 1962;22:1187-92.
26. Conn JW. Aldosteronism in man. Some clinical and climatological aspects. Part II. JAMA 1963;183:871-8.
27. Zwemer RL, Sullivan RC. Blood chemistry of adrenal insufficiency in cats. Endocrinology 1934;18:97-106.
28. Loeb RF. Effect of sodium chloride in treatment of patients with Addison's disease. Proc Soc Exp Biol Med 1933;30:808-12.
29. Loeb RF, Atchley DW, Benedict EM, Leland J. Electrolyte balance studies in adrenalectomized dogs with particular reference to the excretion of sodium. J Exp Med 1933;57:775-92.
30. Harrop GA, Soffer LJ, Ellsworth R,Trescher JH. Studies on the suprarenal cortex. III. Plasma electrolytes and electrolyte excretion during suprarenal insufficiency in the dog. J Exp Med 1933;58:17-38.
31. Conway EJ, Hingerty D. The influence of adrenalectomy on muscle constituents. Biochemistry 1946;40:561-8.
32. DaVanzo JP, Crossfield HC, Swingle WW. Effect of various adrenal steroids on plasma magnesium and the electrocardiogram of adrenalectomized dogs. Endocrinology 1958;63:825-30.
33. Hanna S, MacIntyre I. The influence of aldosterone on magnesium metabolism. Lancet 1960;2(Aug 13):348-50.
34. Wester PO, Dyckner T. Diuretic treatment and magnesium losses. Acta Med Scand Suppl 1981;647:145-52.
35. Leier CV, Dei Cas I., Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J 1994;128:564-74.
36. Wilson JR. Use of antiarrhythmic drugs with heart failure: clinical efficacy, hemodynamic results, and relation to survival. Circulation 1987;75:IV64-IV73.
37. Armanini D, Strasser T, Weber PC. Characterization of aldosterone binding sites in circulating human mononuclear leukocytes. Am J Physiol 1985;248:E388-E390.
38. Armanini D, Witzgall H,Wehling M, Kuhnle U, Weber PC. Aldosterone receptors in different types of primary hyperaldosteronism. J Clin Endocrinol Metab 1987;65:101-04.
39. Armanini D, Zennaro CM, Martella L, Pratesi C, Scali M, Zampollo V. Regulation of aldosterone receptors in hypertension. Steroids 1993;58:611-13.
40. Delva P, Pastori C, Degan M, Montesi G, Brazzarola P, Lechi A. Intralymphocyte free magnesium in patients with primary aldosteronism: aldosterone and lymphocyte magnesium homeostasis. Hypertension 2000;35:113-17.
41. Wodi LA, Ahokas RA, Sun Y, Weber KT. Oxidative stress and peripheral blood mononuclear cell free cytosolic magnesium in rats treated with aldosterone/salt [abstract]. J Investig Med 2003;51(suppl 1):S283.
42. Munir A, Gerling IC, Sun Y, Ali C, Weber KT. Proteomic analysis of peripheral blood mononuclear cell activation in aldosterone-treated rats [abstract]. J Investig Med 2003; 51 (suppl 1):S283.
43. Gerling IC, Sun Y, Ahokas RA et al. Aldosteronism. An immunostimulatory state precedes the proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol 2003;285:H813-H821.
44. Ichihara A, Suzuki H, Saruta T. Effects of magnesium on the renin-angiotensin-aldosterone system in human subjects. J Lab Clin Med 1993;1122:432-40.
45. Corica F, Allegra A, Ientile R et al. Effects of the intravenous magnesium administration on aldosterone and atrial natriuretic factor plasma concentrations. Nephron 1996;73: 739-41.
46. Cantin M. Relationship of juxtaglomerular apparatus and adrenal cortex to biochemical and extracellular fluid volume changes in magnesium deficiency. Lab Invest 1970;22:558-68.
47. Ginn HE, Cade R, McCallum T, Fregley M. Aldosterone secretion in magnesium-deficient rats. Endocrinology 1967;80:969-71.
48. Solounias BM, Schwartz R. The effect of magnesium deficiency on serum aldosterone in rats fed two levels of sodium. Life Sci 1975;17:1211-17.
49. Nadler JL, Buchanan T, Nitarajan R, Antonipillai I, Bergman R, Rude R. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension 1993;21:1024-9.
50. Laurant P, Dalle M, Berthelot A, Rayssiguier Y. Time-course of the change in blood pressure level in magnesium-deficient Wistar rats. Br J Nutr 1999;82:243-51.
51. Atarashi K, Matsuoka H, Takagi M,Sugimoto T. Magnesium ion: a possible physiological regulator of aldosterone production. Life Sci 1989;44:1483-9.
52. MacIntyre I, Davidsson D. The production of secondary potassium depletion, sodium retention, nephrocalcinosis and hypercalcinemia by magnesium deficiency. Biochem J 1958; 70:456-62.
53. Madden JA, Smith GA, Llaurado JG. Myocardial K kinetics in rats on Mg-deficient diet. J Am Coll Nutr 1982;1:323-9.
54. Chang C, Bloom S. Interrelationship of dietary Mg intake and electrolyte homeostasis in hamsters: I. Severe Mg deficiency, electrolyte homeostasis, and myocardial necrosis. J Am Coll Nutr 1985;4:173-85.
55. Hall CE, Hall O. Hypertension and hypersalimentation. I. Aldosterone hypertension. Lab Invest 1965;14:285-94.
56. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res 1990;67:1355-64.
57. Sun Y, Ratajska A, Zhou G,Weber KT. Angiotensin converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone. J Lab Clin Med 1993;122:395-403.
58. Robert V, Van Thiem N, Cheav SL, Mouas C, Swynghedauw B, Delcayre C. Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension 1994;24:30-6.
59. Sun Y, Ramires FJA, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res 1997;35:138-47.
60. Campbell SE, Janicki JS, Weber KT. Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J Mol Cell Cardiol 1995;27:1545-60.
61. Nicoletti A, Mandet C, Challah M, Barity J, Michel J-B. Mediators of perivascular inflammation in the left ventricle of renovascular hypertensive rats. Cardiovasc Res 1996;31:585-95.
62. Fiebeler A, Schmidt F, Müller DN et al. Mineralocorticoid receptor affects AP-1 and nuclear factor-kB activation in angiotensin II-induced cardiac injury. Hypertension 2001;37: 787-93.
63. Rocha R, Stier CT, Jr., Kifor I et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000;141:3871-8.
64. Selye H. Protection by a steroid-spironolactone against certain types of cardiac necroses. Proc Soc Exp Biol Med 1960;104:212-13.
65. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995;269:E657-E662.
66. Benetos A, Lacolley P, Safar ME. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997;17:1152-6.
67. Lacolley P, Safar ME, Lucet B, Ledudal K, Labat C, Benetos A. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 2001;37:662-7.
68. Martinez DV, Rocha R, Matsumura M et al. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension 2002;39:614-18.
69. Rocha R, Rudolph AE, Frierdich GE et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol 2002;283:H1802-H1810.
70. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000;102:2700-06.
71. Thompson JS, Palmieri GM, Eliel LP, Crawford RL. The effect of porcine calcitonin on osteoporosis induced by adrenal cortical steroids. J Bone Joint Surg Am 1972;54:1490-500.
72. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart. Role of oxidative stress. Am J Pathol 2002;161:1773-81.
73. Maisel A, Cesario D, Baird S, Rehman J, Haghighi P, Carter S. Experimental autoimmune myocarditis produced by adoptive transfer of splenocytes after myocardial infarction. Circ Res 1998;82:458-63.
74. Ryan MF, Ryan MP. Lymphocyte electrolyte alterations during magnesium deficiency in the rat. Ir J Med Sci 1979; 148:108-09.
75. Wiles ME, Wagner TL, Weglicki WB. Effect of acute magnesium deficiency (MgD) on aortic endothelial cell (EC) oxidant production. Life Sci 1997;60:221-36.
76. Weglicki WB, Mak IT, Stafford RE, Dickens BF, Cassidy MM, Phillips TM. Neurogenic peptides and the cardiomyopathy of magnesium-deficiency: effects of substance P-receptor inhibition. Mol Cell Biochem 1994;130:103-09.
77. Weglicki WB, Dickens BF, Wagner TL, Chmielinska JJ, Phillips TM. Immunoregulation by neuropeptides in magnesium deficiency: ex vivo effect of enhanced substance P production on circulating T lymphocytes from magnesium-deficient mice. Magnes Res 1996;9:3-11.
78. Mak IT, Komarov AM, Wagner TL, Stafford RE, Dickens BF, Weglicki WB. Enhanced NO production during Mg deficiency and its role in mediating red blood cell glutathione loss. Am J physiol 1996;271:C385-C390.
79. 2+ deficiency by substance P receptor inhibition. Circ Res 1994;74:1009-13.
80. Felder RB, Francis J, Zhang ZH, Wei SG, Weiss RM, Johnson AK. Heart failure and the brain: new perspectives. Am J Physiol 2003;284:R259-R276.
81. Anker SD,Chua TP, Ponikowski P et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96: 526-34.
82. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993;21:929-33.
83. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-7.
84. Bauersachs J, Heck M, Fraccarollo D et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 2002;39:351-8.
85. Weber KT, Singh KD, Hey JC. Idiopathic intracranial hypertension with primary aldosteronism. Report of two cases. Am J Med Sci 2002;324:45-50.
86. Mendonça E, Albuquerque L, Jácombe L, Luís MLS, Rosa FC. Pseudotumor cerebri in a patient with Bartter's syndrome and obesity. Nephron 1996;72:98-9.
87. Gomez-Sanchez CE, Zhou MY, Cozza EN, Morita H, Foecking MF, Gomez-Sanchez EP. Aldosterone biosynthesis in the rat brain. Endocrinology 1997;138:3369-73.
88. Slight SH, Joseph J, Ganjam VK, Weber KT. Extra-adrenal mineralocorticoids and cardiovascular tissue. J Mol Cell Cardiol 1999;31:1175-84.
89. Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodeling. The role of aldosterone. J Mol Cell Cardiol 2002;34:1577-84.
90. Birmingham MK, Sar M, Stumpf WE. Localization of aldosterone and corticostorone in the central nervous system, assessed by quantitative autoradiography. Neurochem Res 1984;9:333-50.
91. Wright EM.Transport processes in the formation of the cerebrospinal fluid. Rev Physiol Biochem Pharmacol 1978;83: 1-34.
92. Vates TS, Jr., Bonting SL, Oppelt WW. Na-K activated adenosine triphosphatase formation of cerebrospinal fluid in the cat. Am J Physiol 1964;206:1165-72.
93. Johanson CE, Reed DJ, Woodbury DM. Active transport of sodium and potassium by the choroid plexus of the rat. J Physiol 1974;241:359-72.
94. Loffreda N, Eldin P, Auzou G, Frelin C, Claire M. Corticosteroid receptors in cells derived from rat brain microvessels: mRNA identification and aldosterone binding. Am J Physiol 1992;262:C156-C163.
95. Ames A, III, Higashi K, Nesbett FB. Effects of PCO2, acetazolamide and ouabain on volume and composition of choroid-plexus fluid. J Physiol 1965;181:516-24.
96. 22Na in the cerebrospinal fluid and the brain. J Physiol 1970;209:131-53.
97. Kageyama Y, Suzuki H, Saruta T. Presence of aldosterone-like immunoreactivity in cerebrospinal fluid in normotensive subjects. Acta Endocrinol 1992;126:501-04.
98. Masuzawa T, SaitoT, Sato F. Cytochemical study on enzyme activity asociated with cerebrospinal fluid secretion in the choroid plexus and ventricular ependyma. Brain Res 1981; 222:309-22.
99. Klarr SA, Ulanski LJ, II, Stummer W, Xiang J, Betz AL, Keep RF. The effects of hypo- and hyperkalemia on choroid plexus potassium transport. Brain Res 1997;758:39-44.
100. Kageyama Y, Bravo EL. Hypertensive mechanisms associated with centrally administered aldosterone in dogs. Hypertension 1988;11:750-3.
101. Gómez-Sánchez EP. Intracerebroventricular infusion of aldosterone induces hypertension in rats. Endocrinology 1986;118:819-23.
102. Zhang ZH, Francis J, Weiss RM, Felder RB. The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure. Am J Physiol 2002;283:H423-H433.
103. Francis J, Weiss RM, Wei SG et al. Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am J Physiol 2001;281: H2241-H2251.
104. Francis J, Weiss RM, Johnson AK, Felder RB. Central mineralocorticoid receptor blockade decreases plasma TNF-α after coronary artery ligation in rats. Am J Physiol 2003;284:R328-R335.
105. Lockett MF. Hormonal actions of the heart and of lungs on the isolated kidney. J Physiol 1967;193:661-9.
106. Lockett MF, Retallack RW. The isolation of a substance very closely resembling the 18-monoacetate of D-aldosterone from the venous blood of activated muscle and from contracting muscle. J Physiol 1969;204:435-42.
107. Lockett MF. Changes in the flow and composition of the urine induced by the 18 monoacetate of D-aldosterone, in cats. J Physiol 1969;202:671-82.
108. Lockett MF, Retallack RW. The influence of heart rate on the secretion of a substance closely resembling the 18-monoacetate of D-aldosterone by the hearts of cats under chloralose anaesthesia. J Physiol 1970;208:21-32.
109. Lockett MF, Retallack RW. Factors controlling the secretion of a substance biologically resembling the 18-monoacetate of D-aldosterone by heart muscle. J Physiol 1970;210:717-25.
110. Lockett MF, Retallack RW. The isolation of a renally active substance from arterial blood. J Physiol 1972;223:49-57.
111. Takeda Y, Miyamori I, Yoneda T et al. Production of aldosterone in isolated rat blood vessels. Hypertension 1995;25:170-3.
112. Takeda Y, Miyamori I, Yoneda T et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 1996;81:2797-800.
113. Silvestre J-S, Robert V, Heymes C et al. Myocardial production of aldosterone and corticosterone in the rat. J Biol Chem 1998;273:4883-91.
114. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994;269:24316-20.
115. Mizuno Y, Yoshimura M, Yasue H et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001;103:72-7.
116. Yoshimura M, Nakamura S, Ito T et al. Expression of aldosterone synthase gene in failing human heart: quantitative analysis using modified real-time polymerase chain reaction. J Clin Endocrinol Metab 2002;87:3936-40.
117. +-dependent 11β-hydroxysteroid dehydrogenase in the human heart. J Mol Cell Cardiol 1996;28:781-7.
118. Sun Y, Cleutjens JPM, Diaz-Arias AA, Weber KT. Cardiac angiotensin converting enzyme and myocardial fibrosis in the rat. Cardiovasc Res 1994;28: 1423-32.
119. Sun Y, Weber KT.Angiotensin II receptor binding following myocardial infarction in the rat. Cardiovasc Res 1994;28:1623-8.
120. Sun Y, Weber KT. Cells expressing angiotensin II receptors in fibrous tissue of rat heart. Cardiovasc Res 1996;31:518-25.
121. Passier RC, Smits JF, Verluyten MJ, Daemen MJ. Expression and localization of renin and angiotensinogen in rat heart after myocardial infarction. Am J Physiol 1996;271:H1040-H1048.
122. Lefroy DC, Wharton J, Crake T et al. Regional changes in angiotensin II receptor density after experimental myocardial infarction. J Mol Cell Cardiol 1996;28:429-40.
123. 1 and repair in the infarcted heart. J Mol Cell Cardiol 1998:30:1559-69.
124. Silvestre J-S, Heymes C, Oubéenaïssa A et al. Activation of cardiac aldosterone production in rat myocardial infarction. Effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999;99:2694-701.
125. Delcayre C, Silvestre JS, Garnier A et al. Cardiac aldosterone production and ventricular remodeling. Kidney Int 2000;57:1346-51.
126. Hayashi M, Tsutamoto T, Wada A et al. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 2001;38:1375-82.
127. Tsutamoto T, Wada A, Maeda K et al. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 2000;36:838-44.
128. Van Belle E, Bauters C, Wernert N et al. Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist. Cardiovasc Res 1995;29:27-32.
129. Slight SH, Chilakamarri VK, Nasr S et al. Inhibition of tissue repair by spironolactone: role of mineralocorticoids in fibrous tissue formation. Mol Cell Biochem 1998;189:47-54.
130. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT, Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31(part 2):451-8.
131. Weber KT. Aldosteronism revisited. Perspectives on less well-recognized actions of aldosterone. J Lab Clin Med 2003:142:71-82.